HLA DR15 (DR2) Immunosuppressive Response Association in Myelodysplastic Syndrome (MDS)
| HLA DR15 (DR2) Immunosuppressive Response Association in Myelodysplastic Syndrome (MDS) | | | |
| Number | | 167100 |
| CPT | | 83890; 83893 (x8); 83896 (x16); 83898; 83912 |
| Related Information | | HLA DRB, DQB Disease Association |
| Synonyms | | Antithymocyte Globulin ; ATG ; Cyclosporine A ; DR15 ; HLA DR15 ; Immunosuppressive Response ; MDS ; Myelodysplastic Syndrome |
| Special Instructions | | When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. Please call 800-533-1037 (HLA Customer Service) to obtain the buccal swab kit or for assistance in selecting the proper HLA test for the patient. |
| Specimen | | Whole blood or buccal swabs |
| Volume | | 7 mL whole blood or four buccal swabs |
| Minimum Volume | | 3 mL whole blood or four buccal swabs |
| Container | | Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. |
| Storage Instructions | | Maintain blood specimen at room temperature. Keep buccal swabs dry and at room temperature. |
| Causes for Rejection | | Hemolysis; clotted specimen; insufficient volume of DNA on buccal swabs |
| Use | | Determine the presence of DR15 antigen. There is an apparent association between successful treatment of myelodysplastic syndromes with immunosuppressive agents, such as cyclosporine A and antithymocyte globulin (ATG), and HLA-DR15. |
| Limitations | | Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for testing. |
| Methodology | | Polymerase chain reaction (PCR)/sequence-specific oligonucleotide probes (SSOP) |
| References | | National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology, Volume 3, 2006. Saunthararajah Y, Nakamura R, Nam JM, et al, “HLA-DR15 (DR2) Is Overrepresented in Myelodysplastic Syndrome and Aplastic Anemia and Predicts a Response to Immunosuppression in Myelodysplastic Syndrome,” Blood, 2002, 100(5):1570-4. |
|